Literature DB >> 35404107

Alternative Splicing of the Aryl Hydrocarbon Receptor Nuclear Translocator (ARNT) Is Regulated by RBFOX2 in Lymphoid Malignancies.

Amy M Cooper1,2, Curtis A Nutter3, Muge N Kuyumcu-Martinez3,4, Casey W Wright1,2.   

Abstract

Aberrant alternative splicing (AS) of pre-mRNAs promotes the development and proliferation of cancerous cells. Accordingly, we had previously observed higher levels of the aryl hydrocarbon receptor nuclear translocator (ARNT) spliced variant isoform 1 in human lymphoid malignancies compared to that in normal lymphoid cells, which is a consequence of increased inclusion of alternative exon 5. ARNT is a transcription factor that has been implicated in the survival of various cancers. Notably, we found that ARNT isoform 1 promoted the growth and survival of lymphoid malignancies, but the regulatory mechanism controlling ARNT AS is unclear. Here, we report cis- and trans-regulatory elements which are important for the inclusion of ARNT exon 5. Specifically, we identified recognition motifs for the RNA-binding protein RBFOX2, which are required for RBFOX2-mediated exon 5 inclusion. RBFOX2 upregulation was observed in lymphoid malignancies, correlating with the observed increase in ARNT exon 5 inclusion. Moreover, suppression of RBFOX2 significantly reduced ARNT isoform 1 levels and cell growth. These observations reveal RBFOX2 as a critical regulator of ARNT AS in lymphoid malignancies and suggest that blocking the ARNT-specific RBFOX2 motifs to decrease ARNT isoform 1 levels is a viable option for targeting the growth of lymphoid malignancies.

Entities:  

Keywords:  ARNT; RBFOX2; alternative splicing; lymphoid malignancies

Mesh:

Substances:

Year:  2022        PMID: 35404107      PMCID: PMC9119065          DOI: 10.1128/mcb.00503-21

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   5.069


  40 in total

Review 1.  Mechanisms of alternative pre-messenger RNA splicing.

Authors:  Douglas L Black
Journal:  Annu Rev Biochem       Date:  2003-02-27       Impact factor: 23.643

2.  The aryl hydrocarbon receptor nuclear translocator (Arnt) is required for tumor initiation by benzo[a]pyrene.

Authors:  Shengli Shi; Diana Y Yoon; Kimberly C Hodge-Bell; Ilona G Bebenek; Michael J Whitekus; Ruixue Zhang; Alistair J Cochran; Sara Huerta-Yepez; Sun-Hee Yim; Frank J Gonzalez; Anil K Jaiswal; Oliver Hankinson
Journal:  Carcinogenesis       Date:  2009-09-15       Impact factor: 4.944

3.  The RNA-binding protein Rbfox2: an essential regulator of EMT-driven alternative splicing and a mediator of cellular invasion.

Authors:  C Braeutigam; L Rago; A Rolke; L Waldmeier; G Christofori; J Winter
Journal:  Oncogene       Date:  2013-02-25       Impact factor: 9.867

Review 4.  Developmental regulation of RNA processing by Rbfox proteins.

Authors:  John G Conboy
Journal:  Wiley Interdiscip Rev RNA       Date:  2016-10-17       Impact factor: 9.957

5.  Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues.

Authors:  Xijin Ge; Shogo Yamamoto; Shuichi Tsutsumi; Yutaka Midorikawa; Sigeo Ihara; San Ming Wang; Hiroyuki Aburatani
Journal:  Genomics       Date:  2005-08       Impact factor: 5.736

6.  Expression of aryl hydrocarbon receptor nuclear translocator enhances cisplatin resistance by upregulating MDR1 expression in cancer cells.

Authors:  Ya-Yi Chan; Sriram Kalpana; Wei-Chiao Chang; Wen-Chang Chang; Ben-Kuen Chen
Journal:  Mol Pharmacol       Date:  2013-08-01       Impact factor: 4.436

7.  Rbfox proteins regulate alternative mRNA splicing through evolutionarily conserved RNA bridges.

Authors:  Michael T Lovci; Dana Ghanem; Henry Marr; Justin Arnold; Sherry Gee; Marilyn Parra; Tiffany Y Liang; Thomas J Stark; Lauren T Gehman; Shawn Hoon; Katlin B Massirer; Gabriel A Pratt; Douglas L Black; Joe W Gray; John G Conboy; Gene W Yeo
Journal:  Nat Struct Mol Biol       Date:  2013-11-10       Impact factor: 15.369

8.  Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients.

Authors:  André Kahles; Kjong-Van Lehmann; Nora C Toussaint; Matthias Hüser; Stefan G Stark; Timo Sachsenberg; Oliver Stegle; Oliver Kohlbacher; Chris Sander; Gunnar Rätsch
Journal:  Cancer Cell       Date:  2018-08-02       Impact factor: 31.743

9.  The aryl hydrocarbon receptor nuclear translocator (ARNT) modulates the antioxidant response in AML cells.

Authors:  Chunhong Gu; Joelle Gonzalez; Tong Zhang; Suzanne Kamel-Reid; Richard A Wells
Journal:  Leuk Res       Date:  2013-10-22       Impact factor: 3.156

10.  Drug metabolism and clearance system in tumor cells of patients with multiple myeloma.

Authors:  Wafa Hassen; Alboukadel Kassambara; Thierry Reme; Surinder Sahota; Anja Seckinger; Laure Vincent; Guillaume Cartron; Jérôme Moreaux; Dirk Hose; Bernard Klein
Journal:  Oncotarget       Date:  2015-03-20
View more
  1 in total

1.  FOXD1 Is a Transcription Factor Important for Uveal Melanocyte Development and Associated with High-Risk Uveal Melanoma.

Authors:  Quincy C C van den Bosch; Josephine Q N Nguyen; Tom Brands; Thierry P P van den Bosch; Robert M Verdijk; Dion Paridaens; Nicole C Naus; Annelies de Klein; Emine Kiliç; Erwin Brosens
Journal:  Cancers (Basel)       Date:  2022-07-28       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.